A systematic review and integrative approach to decode the common molecular link between levodopa response and Parkinson’s disease

Table 2 Characteristics of included studies for assessment of association between genetic variants and LR in PD

Study	Population/Ethnicity	Response criteria	Age^a (years)	Gender		Number of samples			Genes	Studied variants	p-value	OR (95% CI)	Dose^a (Drug)	Treatment length (year)	Score
Study	Population/Ethnicity	Response criteria	Age^a (years)	M	F	Total	R	NR	Genes	Studied variants	p-value	OR (95% CI)	Dose^a (Drug)	Treatment length (year)	Score
Tan EK et al. [48]	Singapore	UPDRS	69.9±7.6	24	15	39	NA	NA	*COMT*	rs4680	0.004	-	7.37 mg/ week (P); 421.5 ± 226.2mg (L)	at least 3 months	12
Liu YZ et al. [51]	Chinese	UPDRS-I, HY <2.5	61.90 ± 8.20	14	16	30	11	19	*DRD3*	rs6280 (Ser/Ser)	0.024	9.75( 1.60- 59.70) ^*	0.125mg/thrice a day (L, B,P)	> 3 months	12
Devos D et al. [52]	Caucasian	UPDRS-III, HY	>30	23	10	33	14	19	*DDC*	rs921451	0.048	-	NA (L,B)	NA	13
Devos D et al. [52]	Caucasian	UPDRS-III, HY	>30	23	10	33	8	25	*DDC*	rs3837091	0.048	-	NA (L,B)	NA	13
Moreau C et al. [54]	French	UPDRS II, III	60-63	NA	NA	61	NA	NA	*SLC6A3*	rs28363170	0.005	-	710 ± 90.8mg/day (L)	16-17	12
Moreau C et al. [54]	French	UPDRS II, III	60-63	NA	NA	61	NA	NA	*SLC6A3*	rs3836790	<0.001	-	710 ± 90.8mg/day (L)	16-17	12

M male, F female, R responder, NR non-responder, bp base pair; Dose of drug are in mg/day. Unit of Age, Dose and Follow up period are represented with Mean ± standard deviation; ^a unit of age and dose are represented with Mean ± standard deviation; OR, Odds Ratio; *OR calculated using reported frequencies from the respective article; UPDRS Unified Parkinson’s disease rating scale, HY Hoehn and Yahr Staging of Parkinson's Disease; Drugs are L-levodopa, C-carbidopa, A-amantadine, T-, DA-Dopamine Agonist, MBI-MAO-B inhibitor, S-Selegiline, R-Ropinirole, E-Entacapone, P-Pramipexole; PCR-RFLP, Polymerase chain reaction- Restriction fragment length polymorphism. NA No Association; -,Insufficient data. Bold are significant polymorphisms (p≤ 0.05) and their corresponding genes

ISSN: 1755-8794